BACKGROUND: Oral refeeding in patients recovering from acute pancreatitis may cause pain relapse. Patients with pain relapse may be ill for prolonged periods, thereby consuming additional health care resources. We aimed to determine the incidence and risk factors of pain relapse on the basis of reviewing all studies on oral refeeding in acute pancreatitis.
INTRODUCTION
During the last decade, artificial nutrition in patients with acute pancreatitis has shifted from a tool to provide calories to a strong therapeutic device, aiming at reducing complications and promoting faster recovery and resolution of the disease process (1, 2) . However, up to now one of the unanswered questions in the nutritional management of acute pancreatitis is the optimal timing of oral refeeding (3, 4) .
In general, oral intake of limited amounts of calories is initiated when abdominal pain has subsided, parenteral narcotics are no longer required, abdominal tenderness has markedly decreased, nausea and vomiting have ceased, and/or bowel sounds are present (5) . The current ESPEN guidelines state that in mild acute pancreatitis "oral food intake should be tried as soon as possible" (6) . Nonetheless, premature initiation of oral refeeding may stimulate pancreatic secretion and leading to the relapse of pain as well as prolongation of the hospital stay, thereby increasing treatment costs (7) . Future
The present review demonstrates the high incidence of pain relapse after oral refeeding in patients with acute pancreatitis and underlines the need for further high quality clinical trials on the use of nutritional support in acute pancreatitis.
To access a continuing medical education exam for this article, please visit www.acg.gi.org/journalcme. trials will have to address these issues. Before such studies can be initiated baseline data on the effects of oral refeeding are needed. To that extent this review was conducted, it assesses the incidence and risk factors of pain relapse after oral refeeding in patients with acute pancreatitis.
METHODS
We aimed to identify all relevant studies on oral refeeding in patients with acute pancreatitis. A computerized English literature search of the Cochrane Central Register of Controlled Trials, EMBASE, and Medline until December 31, 2006 was conducted using predefined search terms. The search strategy for PubMed was "acute pancreatitis"(Title/Abstract) or "pancreatitis"(Title/Abstract) and "refeeding"(Title/Abstract). The search strategy for Embase included next terms: "acute pancreatitis" and "refeeding" and [humans]/lim. The search strategy in Cochrane library was "acute pancreatitis" and "refeeding." Bibliographies of all selected articles that included information on oral refeeding in acute pancreatitis were reviewed for other relevant articles. The abstracts of major gastroenterological meetings (DDW, UEGW) since 2001 were also screened. The following selection criteria were used to identify published studies for inclusion in this analysis: (a) study design: prospective, (b) population: patients with acute pancreatitis, (c) intervention: oral refeeding, and (d) outcome variables: the frequency of pain relapse and length of hospital stay. Records extracted by the initial search were scanned to exclude obviously irrelevant studies, and then trials potentially meeting the inclusion criteria were identified. Full-text articles were retrieved and reviewed by two authors (MSP and HCvS) for the purpose of applying inclusion criteria independently. All differences were resolved by discussion among the authors of this review. Data from the studies were extracted using standardized forms.
RESULTS
A total of 17 publications were identified through the literature search. Fourteen of 17 publications were subsequently excluded because they were guidelines, editorials, or studies in which the outcome variables were not reported. A total of three trials were included in the review (8) (9) (10) . The characteristics of included studies are presented in Table 1 . Overall, 274 patients with acute pancreatitis were enrolled in these trials ( Table 2 ). The primary end point of all studies was the incidence of pain relapse during an attack of acute pancreatitis. The treatment protocol of each study stated that oral feeding could be commenced at the decision of the responsible physician. No advice concerning optimal timing was given. Sixty of 274 patients (21.9%) suffered from a pain relapse during the course of disease. This percentage ranged from 21% to 27% among studies (24.3% on average). In 47 of 60 (78.3%) patients with pain relapse, this occurred within 48 h after refeeding was started (Table 3) . Levy et al. (8) carried out the first nonrandomized study assessing the frequency and risk factors of pain relapse during the refeeding period in patients with acute pancreatitis after a fasting period >48 h. Twenty-one percent of patients (24 of 116) presented a pain relapse and 12.0 ± 0.8 days delay between onset of symptoms and oral refeeding. The authors proposed the following formula in predicting the pain after refeeding: 0.64a + 1.11b + 2.18c -9.06, where a = Balthazar's CT score, b = duration of painful period, c = serum lipase concentration on the day before refeeding <3 times the upper normal limit, and 9.06 = constant.
Pandey et al. (9) performed a randomized controlled trial to compare oral (N = 15) and jejunal tube (N = 13) nutrition in relation to refeeding pain in patients with acute pancreatitis. The median duration between onset of symptoms and start of refeeding was 5 (5-18) days in the oral refeeding group and 7 (6-17) days in the enteral-tube-refeeding group. There were no complications of enteral feeding. None of the patients in the enteral refeeding group had pain relapse, in comparison to 4 of 15 patients in the oral refeeding group (P = 0.06), but this may be due to a type II error. Mean length of hospital stay also tended to be shorter in the enterally refed group (12 ± 5 days vs 21 ± 18 days).
A recent prospective nonrandomized trial by Chebli et al. (10) aimed to assess the risk factors for pain relapse after oral refeeding in patients convalescing with mild acute pancreatitis. Mean number of days of abdominal pain before oral refeeding was 4.2 ± 0.9 in patients with pain relapse and 4 ± 2.7 in patients without pain relapse. According to the logistic regression model, the independent risk factors of pain relapse were presence of peripancreatic fluid collection, serum CRP on the fourth day, and serum lipase concentration on the day of oral refeeding. All 32 patients with pain relapse were man- aged with nasojejunal feeding (N = 27) or total parenteral nutrition (N = 5). The authors stated that nutritional support was well tolerated without adverse effects on the course of acute pancreatitis. In each study a comparative analysis of patients with and without pain relapse was carried out (Table 4) . Two studies (8,9) demonstrated a significantly higher Balthazar's CT score at admission in the group with pain relapse, whereas all three trials found no difference in the severity scores between patients with and without pain relapse. All studies also found a significantly longer length of hospital stay in patients with pain relapse. Two of them (8, 9) also reported that the hospital stay after the first attempt of oral refeeding, as well as the total duration of pain, were significantly prolonged in patients with pain relapse.
DISCUSSION
This first review on oral refeeding after the onset of acute pancreatitis reveals that pain relapse during oral refeeding occurs in about one-fifth of patients. Notably, patients that experience pain relapse stay longer in the hospital. Unfortunately, the clinical signs of disease have no predictive value in the detection of patients that will develop pain relapse after oral refeeding. Also, the laboratory and CT predictive factors of pain relapse have no consistency, do not provide a cutoff level of parameters, and thereby cannot be readily implemented in day-to-day practice.
The pathophysiology of pain relapse in acute pancreatitis is still unclear. Because patients with pain relapse tended to have a longer duration of initial abdominal pain (10), persistent elevation of serum enzymes (10) , and higher Balthazar's scores on admission (8, 9) , it may well be that patients with pain relapse are those with more severe acute pancreatitis (11) . However, due to the significantly longer postrefeeding length of hospital stay (8, 9) and the absence of difference in the severity scores between patients with and without pain relapse (8) (9) (10) , premature oral refeeding could also be responsible for the pain relapse. Refeeding pain may be caused by restimulation of pancreatic secretion by oral bolus feeding, which may activate both dormant enzymes and the inflammatory process (12) . It is suggested that if refeeding pain is to be prevented the following aspects have to be taken into account: mechanical tolerance (e.g., absence of bloating, nausea, vomiting, abdominal distension, or ileus), biochemical tolerance (e.g., absence of secondary electrolyte or other metabolic derangements), and tolerance involving assimilation (e.g., adequate absorption and absence of diarrhea) (13) .
In an attempt to prevent pain relapse in acute pancreatitis after oral refeeding, a French research group suggested the use of a long-acting somatostatin analogue (14) . In their study, only 1 of 23 (4.3%) patients treated with one intramuscular injection of lanreotide 30 mg on the day before refeeding had a recurrence of pain from acute pancreatitis, but 15 (65.2%) patients also experienced at least one adverse effect from the drug. Since this was an uncontrolled pilot study, a multicenter randomized placebo-controlled double-blind trial was undertaken further (15) . Unfortunately, the injection of lanreotide 30 mg 24 h prior to oral refeeding had no influence on either the rate of pain relapse within the week following oral refeeding or the length of hospital stay.
A possible alternative strategy to prevent pain relapse is the use of enteral tube feeding. A recent randomized trial by Pandey et al. (9) compared oral bolus refeeding (started 5 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] days after the onset of acute pancreatitis) and jejunal refeeding (started on 7 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] days) and found a lower risk of pain relapse in jejunally refeed patients. Further, a randomized trial by Eatock et al. (16) demonstrated no difference in pain and analgesic requirement between early nasogastric and nasojejunal tube feeding administered within 72 h after onset of pain in patients with severe acute pancreatitis. Notably, it showed that pain measured by visual analogue score decreased markedly from 7 on the first day to 0 on the third day of nutrition in both groups. Similarly, the mean analgesic requirement in the nasojejunal and nasogastric groups was 0 mg of pethidine on the third day of enteral feeding.
There is reason to believe that enteral feeding is superior to parenteral feeding (that is not different from the nil-permouth regimen in terms of the gut rest) in improving the tolerance of oral refeeding in patients with acute pancreatitis. A randomized controlled trial from the United States (17) demonstrated that reintroduction of oral feeding was better tolerated in those patients who were randomized to enteral feeding, with 80% (21 of 26) advancing to an oral diet without problem, in comparison to 63% (17 of 27) in the parenterally fed group. Further, in the trial by Gupta et al. (18) , 17 patients with acute pancreatitis were randomized (9 in the enterally fed group, 8 in the parenterally fed group). Enteral nutrition was initiated within 6 h of admission and led to no nutritionassociated complications. Bowel function returned to normal more quickly in the enteral nutrition group as evidenced by passing flatus (1 [0-2] days vs 2 [1] [2] [3] [4] [5] days, P = 0.07) and stool (2 [0-3] days vs 3 [2-9] days, P = 0.01) as well as by resumption of full oral intake (2 [0-3] days vs 3 [2] [3] [4] [5] [6] [7] [8] [9] days, P = 0.02). Fatigue, estimated by visual analogue score, improved more rapidly in the enteral than in the parenteral group (significantly different on day 3, P = 0.01). Further, when gastrointestinal motility is not impaired, orally administered enteral polymeric formula, provided on day 2 after admission, is feasible and leads to no clinical or biochemical deterioration in most patients with acute pancreatitis (19) .
The apparent benefit of enteral tube feeding is in keeping with current views on the importance of luminal nutrition for the stimulation of postprandial gut motility (20) . The potential consequence of impaired intestinal motility, as evidenced by disturbance in the migrating motor complex (often referred to as "the housekeeper of the gut") is decreased gut propulsion (21) (22) (23) . There is substantial evidence that migrating motor complex's cycle length during acute pancreatitis and/or starvation is significantly decreased and that this may lead to less proximal propulsion, small bowel bacterial overgrowth, and bacterial translocation (22, 24, 25) . Together with mucosal barrier dysfunction and reduced immune response this may drive to a local inflammatory response and eventually to SIRS and organ failure in patients with acute pancreatitis (25, 26) . Thus, these data question the rationale of fasting patients with acute pancreatitis prior to oral refeeding.
Another relevant issue in acute pancreatitis is the cost of treatment. Two-thirds of the actual cost of treatment is attributable to hospitalization (27) . Recently, Jacobson et al. (28) randomized 121 patients with a mild course of disease to receive either a clear liquid diet or a low-fat solid diet and found that the initiation of feeding with a low-fat solid diet was as well tolerated as a clear liquid diet, but did not result in a shorter length of hospital stay. Hypothetically, the administration of enteral tube feeding, by prevention (attenuation) of ileus and/or improving the tolerance of oral refeeding, should reduce the risk of pain relapse after acute pancreatitis and, likely, the length of hospital stay in this category of patients (Fig. 1) . Taking into account that 80-85% of patients with acute pancreatitis have an uneventful course of disease but nevertheless usually need 5-7 days of hospitalization (29, 30) , such an approach might provide considerable fund savings.
In conclusion, the present review has identified a 22% rate of pain relapse after oral refeeding in patients with acute pancreatitis that is associated with a significant increase in hospital stay. Enteral nutrition might be a valuable modality to reduce a risk of pain relapse, thereby potentially shortening the length of hospital stay. Further, adequately powered studies are needed to address this question and assess whether such an approach will be cost-effective.
